Preliminary Prospectus for Underwritten Offering Reveals $108.8M Cash Position and Runway into 2030
YARW sits 85% above its 52-week low of $14.63 on elevated volume (26× avg).
Summary
Yarrow Bioscience's preliminary prospectus for its underwritten offering of common stock and pre-funded warrants discloses a preliminary cash balance of $108.8 million and expected runway into 2030.
Key Events · Financing and Capital Events · YARW
-
Preliminary Prospectus for Underwritten Offering
A preliminary 424B5 prospectus supplement was filed for an underwritten offering of common stock and pre-funded warrants, with all pricing terms left blank pending finalization. The offering was announced September 10 and priced September 11 at $26.00 per share for 5.77 million shares.
-
Cash Estimate of $108.8M
The filing discloses a preliminary cash and cash equivalents estimate of approximately $108.8 million as of August 31, 2026, up from $18.7 million as of June 30, 2026, reflecting proceeds from the VYNE merger and other financing activities.
-
Runway Extended into 2030
Management expects net proceeds from this offering, combined with existing cash, to fund operations into 2030, including completion of the Phase 2b Graves' disease trial and preparatory work for the next planned thyroid eye disease study.
-
30-Day ATM Standstill
The company agreed not to make any sales under its $50 million Amended and Restated Sales Agreement (ATM) with TD Securities for 30 days from the date of the prospectus supplement, unless the underwriters exercise their option in full.
Analysis · YARW · Life Sciences
The preliminary prospectus supplement for Yarrow Bioscience's underwritten public offering of common stock and pre-funded warrants—announced September 10 and priced September 11 at $26.00 per share—adds several material details. A preliminary cash estimate of $108.8 million as of August 31, 2026 (up from $18.7 million at June 30) is disclosed, and management expects offering proceeds plus existing cash to fund operations into 2030, including completion of the Phase 2b Graves' disease trial. The company also agreed to a 30-day standstill on its $50 million ATM program. While the offering is dilutive to existing holders, the extended cash runway removes near-term financing risk for a clinical-stage biotech.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, YARW was trading at $27.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.1M. The 52-week trading range was $14.63 to $46.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.